Drug Trial Radar · NCT04375436
Safety and Tolerability of NTRX-07 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 10, 2019
Primary completion
May 15, 2020
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- NeuroTherapia, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Integrium; Orange County Research Center
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, placebo-controlled, modified parallel-design single ascending dose (SAD) in adult healthy volunteers (HVs).
Conditions
- Pain, Neuropathic
Interventions
NTRX-07-SDDDrug
NTRX-07-SDD for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with treatment emergent adverse events of NTRX-07Time frame: Seven days
- Number of subjects with Treatment related subjective effects of NTRX-07Time frame: Seven days
- Plasma levels of NTRX-07Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Orange County Research Center
Tustin, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.